Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Liver Neoplasms: Tumors or cancer of the LIVER.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)alpha-Fetoproteins: The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Chemoembolization, Therapeutic: Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Adenoma, Liver Cell: A benign epithelial tumor of the LIVER.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Cell Line, Tumor: A cell line derived from cultured tumor cells.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Liver: A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Hep G2 Cells: A human liver tumor cell line used to study a variety of liver-specific metabolic functions.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Iodized Oil: A preparation of oil that contains covalently bound IODINE. It is commonly used as a RADIOCONTRAST AGENT and as a suspension medium for CHEMOTHERAPEUTIC AGENTS.Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Phenylurea Compounds: Compounds that include the amino-N-phenylamide structure.Niacinamide: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Liver Transplantation: The transference of a part of or an entire liver from one human or animal to another.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Lung Neoplasms: Tumors or cancer of the LUNG.Benzenesulfonates: Organic salts and esters of benzenesulfonic acid.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Hepatitis B virus: The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.Breast Neoplasms: Tumors or cancer of the human BREAST.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Glypicans: A family of GLYCOSYLPHOSPHATIDYLINOSITOL-anchored, cell-surface heparan sulfate proteoglycans that may play a role in CELL GROWTH PROCESSES and CELL DIFFERENTIATION by modulating ligand-receptor interactions.Hepatocytes: The main structural component of the LIVER. They are specialized EPITHELIAL CELLS that are organized into interconnected plates called lobules.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.DNA, Neoplasm: DNA present in neoplastic tissue.Liver Diseases: Pathological processes of the LIVER.Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Ethiodized Oil: Ethyl ester of iodinated fatty acid of poppyseed oil. It contains 37% organically bound iodine and has been used as a diagnostic aid (radiopaque medium) and as an antineoplastic agent when part of the iodine is 131-I. (From Merck Index, 11th ed)Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Carcinoma, Embryonal: A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Colonic Neoplasms: Tumors or cancer of the COLON.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Mouth Neoplasms: Tumors or cancer of the MOUTH.Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Portal Vein: A short thick vein formed by union of the superior mesenteric vein and the splenic vein.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Stomach Neoplasms: Tumors or cancer of the STOMACH.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Focal Nodular Hyperplasia: Solitary or multiple benign hepatic vascular tumors, usually occurring in women of 20-50 years of age. The nodule, poorly encapsulated, consists of a central stellate fibrous scar and normal liver elements such as HEPATOCYTES, small BILE DUCTS, and KUPFFER CELLS among the intervening fibrous septa. The pale colored central scar represents large blood vessels with hyperplastic fibromuscular layer and narrowing lumen.Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.Carcinoma, Verrucous: A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)Hepatitis, Chronic: INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Adenoma, Bile Duct: A benign tumor of the intrahepatic bile ducts.Skin Neoplasms: Tumors or cancer of the SKIN.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Hepatitis B Surface Antigens: Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.Genes, p53: Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.RNA, Neoplasm: RNA present in neoplastic tissue.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Hepatic Artery: A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Carcinogens: Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Transplantation, Heterologous: Transplantation between animals of different species.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Up-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Catheter Ablation: Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.Hepatitis: INFLAMMATION of the LIVER.Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.Gallbladder Neoplasms: Tumors or cancer of the gallbladder.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Mice, Inbred BALB CTransfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Rats, Inbred F344Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Promoter Regions, Genetic: DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.Embryonal Carcinoma Stem Cells: The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Oligonucleotide Array Sequence Analysis: Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.Genes, Tumor Suppressor: Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Hepatoblastoma: A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)Carcinoma, Papillary, Follicular: A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)beta Catenin: A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Bile Ducts, Intrahepatic: Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.Hepacivirus: A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Keratin-7: A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.Cadherins: Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Necrosis: The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrolled action of degradative ENZYMES, leading to MITOCHONDRIAL SWELLING, nuclear flocculation, and cell lysis. It is distinct it from APOPTOSIS, which is a normal, regulated cellular process.Aflatoxins: Furano-furano-benzopyrans that are produced by ASPERGILLUS from STERIGMATOCYSTIN. They are structurally related to COUMARINS and easily oxidized to an epoxide form to become ALKYLATING AGENTS. Members of the group include AFLATOXIN B1; aflatoxin B2, aflatoxin G1, aflatoxin G2; AFLATOXIN M1; and aflatoxin M2.Liver Function Tests: Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions.Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)Infusions, Intra-Arterial: Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.China: A country spanning from central Asia to the Pacific Ocean.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Alanine Transaminase: An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Proportional Hazards Models: Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.Tongue Neoplasms: Tumors or cancer of the TONGUE.Cell Cycle: The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Pyridines: Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.Liver Cirrhosis, Alcoholic: FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.Carcinogenicity Tests: Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.Contrast Media: Substances used to allow enhanced visualization of tissues.Drug-Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.MicroRNAs: Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.Injections, Intralesional: Injections introduced directly into localized lesions.Trans-Activators: Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins.DNA, Viral: Deoxyribonucleic acid that makes up the genetic material of viruses.Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.Bronchial Neoplasms: Tumors or cancer of the BRONCHI.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Embolization, Therapeutic: A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage.Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.

Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. (1/11254)

OBJECTIVE: This study aimed to evaluate the long-term results of treatment and prognostic factors in patients with intrahepatic recurrence after curative resection of hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: Recent studies have demonstrated the usefulness of re-resection, transarterial oily chemoembolization (TOCE), or percutaneous ethanol injection therapy (PEIT) in selected patients with intrahepatic recurrent HCC. The overall results of a treatment strategy combining these modalities have not been fully evaluated, and the prognostic factors determining survival in these patients remain to be clarified. METHODS: Two hundred and forty-four patients who underwent curative resection for HCC were followed for intrahepatic recurrence, which was treated aggressively with a strategy including different modalities. Survival results after recurrence and from initial hepatectomy were analyzed, and prognostic factors were determined by univariate and multivariate analysis using 27 clinicopathologic variables. RESULTS: One hundred and five patients (43%) with intrahepatic recurrence were treated with re-resection (11), TOCE (71), PEIT (6), systemic chemotherapy (8) or conservatively (9). The overall 1-year, 3-year, and 5-year survival rates from the time of recurrence were 65.5%, 34.9%, and 19.7%, respectively, and from the time of initial hepatectomy were 78.4%, 47.2%, and 30.9%, respectively. The re-resection group had the best survival, followed by the TOCE group. Multivariate analysis revealed Child's B or C grading, serum albumin < or = 40 g/l, multiple recurrent tumors, recurrence < or = 1 year after hepatectomy, and concurrent extrahepatic recurrence to be independent adverse prognostic factors. CONCLUSIONS: Aggressive treatment with a multimodality strategy could result in prolonged survival in patients with intrahepatic recurrence after curative resection for HCC. Prognosis was determined by the liver function status, interval to recurrence, number of recurrent tumors, any concurrent extrahepatic recurrence, and type of treatment.  (+info)

Identification of a cAMP response element within the glucose- 6-phosphatase hydrolytic subunit gene promoter which is involved in the transcriptional regulation by cAMP and glucocorticoids in H4IIE hepatoma cells. (2/11254)

The expression of a luciferase reporter gene under the control of the human glucose 6-phosphatase gene promoter was stimulated by both dexamethasone and dibutyryl cAMP in H4IIE hepatoma cells. A cis-active element located between nucleotides -161 and -152 in the glucose 6-phosphatase gene promoter was identified and found to be necessary for both basal reporter-gene expression and induction of expression by both dibutyryl cAMP and dexamethasone. Nucleotides -161 to -152 were functionally replaced by the consensus sequence for a cAMP response element. An antibody against the cAMP response element-binding protein caused a supershift in gel-electrophoretic-mobility-shift assays using an oligonucleotide probe representing the glucose 6-phosphatase gene promoter from nucleotides -161 to -152. These results strongly indicate that in H4IIE cells the glucose 6-phosphatase gene-promoter sequence from -161 to -152 is a cAMP response element which is important for the regulation of transcription of the glucose 6-phosphatase gene by both cAMP and glucocorticoids.  (+info)

Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (3/11254)

Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients.  (+info)

Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. (4/11254)

p53 alterations are considered to be predictive of poor prognosis in hepatocellular carcinoma (HCC) and may induce a humoral response. Anti-p53 serum antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using purified recombinant human p53 on 130 European HCC patients before treatment and during the clinical course of the disease. p53 immunohistochemistry was performed on tumours from the 52 patients who underwent surgery, and DNA sequencing analysis was initiated when circulating anti-p53 antibodies were detected. Nine (7%) HCC patients had anti-p53 serum antibodies before treatment. During a mean period of 30 months of follow-up, all the negative patients remained negative, even when recurrence was observed. Of the nine positive patients, eight were still positive 12-30 months after surgery. The presence of anti-p53 serum antibodies was correlated neither with mutation of the p53 gene nor the serum alpha-fetoprotein levels and clinicopathological characteristics of the tumours. However, a greater incidence of vascular invasion and accumulation of p53 protein were observed in the tumours of these patients (P<0.03 and P<0.01 respectively) as well as a better survival rate without recurrence (P = 0.05). In conclusion, as was recently shown in pancreatic cancer, anti-p53 serum antibodies may constitute a marker of relative 'good prognosis' in a subgroup of patients exhibiting one or several markers traditionally thought to be of bad prognosis.  (+info)

Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. (5/11254)

Wild-type (wt) p53 frequently induces apoptosis when expressed in tumor cells whereas mutant p53 acts as an oncoprotein and consequently, stimulates cell proliferation. We report here exceptions to that rule. p53 conformational mutant 175H and DNA contact mutant 273H provoke apoptosis in human p53-deficient Hep3B hepatoma cells with delayed kinetics relative to wt p53. Similarly, c-Myc strongly stimulates apoptosis in these cells. In contrast, viral oncoproteins E1A and E7, and the cellular oncoprotein MDM-2, fail to elicit cytocidal responses. Efficient apoptotic cell death by mutant p53 requires oligomerization as 175H and 273H with deletions between amino acid residues 326 and 347 of the oligomerization domain are nontoxic. Apoptosis by mutant or wt p53 was significantly inhibited by the serine protease inhibitor AEBSF but not by the inactive analog AEBSA. Together, these results suggest that a wt p53-independent control mechanism is operational in Hep3B cells that eliminates cells upon sensing illegitimate proliferation signals originating from certain oncoproteins, including mutant p53 and Myc. We suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.  (+info)

Enhanced mitochondrial biogenesis is associated with increased expression of the mitochondrial ATP-dependent Lon protease. (6/11254)

Rats bearing the Zajdela hepatoma tumor and T3-treated hypothyroid rats were used to study the role of protein degradation in the process of mitochondrial biogenesis. It was shown that the activity, protein and mRNA levels of the ATP-dependent Lon protease increased in rapidly growing Zajdela hepatoma cells. The increase in the rate of mitochondrial biogenesis by thyroid hormone was similarly accompanied by enhanced expression of the Lon protease. The results imply that mitochondrial biogenesis in mammalian cells is, at least partially, regulated by the matrix Lon protease.  (+info)

Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2. (7/11254)

1. Previous studies of the regulation of the alpha2C-adrenoceptor in OK and in transfected cells have led to discrepant conclusions. In the present work, we examined the homologous regulation of the human alpha2C-adrenoceptor in the hepatocarcinoma cell-line, HepG2; a model which expresses this subtype spontaneously. 2. Short-period treatment of the cells with UK14304 provoked neither a diminution of the potency of the alpha2-agonist to inhibit forskolin-induced cyclic AMP-accumulation nor a change in the degree of receptor coupling to G-proteins. 3. Long-period exposure to UK14304 resulted in a large reduction of [3H]MK912 binding sites (55% decrease). The action of UK14304 was dose-dependent (EC50 = 190 +/- 45 nM), rapid (t1/2 = 4.2 h) and reversible. Receptor down-regulation was also observed with clonidine or (-)adrenaline (38 and 36% decrease, respectively) and was blocked by the addition of alpha2-antagonists. 4. Conversely to that observed with alpha2-agonists, treatment of the cells with RX821002 or yohimbine alone, but not with phentolamine, promoted a significant increase of the receptor expression. 5. The observed alterations of receptor density are not the reflection of changes at the alpha2C4 mRNA level. Estimation of the receptor protein turnover and measurement of its half-life demonstrated that down-regulation by alpha2-agonists and up-regulation by alpha2-antagonists, with inverse-agonist efficacy, are respectively the consequence of increased and decreased rate of receptor degradation. 6. In conclusion, our data show that alpha2C-adrenoceptor does not undergo desensitization but is down-regulated in HepG2. The lack of desensitization agrees with previous results obtained in cells transfected with the alpha2C4 gene, but not with observations made in OK cells. Inversely, down-regulation fits with results obtained in OK but not in transfected cells. The reasons for these discrepancies are discussed. Our results also demonstrated that certain alpha2-antagonists behave as inverse agonist on the HepG2 model and thus provide for the first time evidence of inverse efficacy of antagonists on a cellular model expressing physiological level of a wild-type alpha2-adrenoceptor.  (+info)

Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. (8/11254)

The liver-type fatty acid binding protein (L-FABP), a member of a family of mostly cytosolic 14-15 kDa proteins known to bind fatty acids in vitro and in vivo, is discussed to play a role in fatty acid uptake. Cells of the hepatoma HepG2 cell line endogenously express this protein to approximately 0.2% of cytosolic proteins and served as a model to study the effect of L-FABP on fatty acid uptake, by manipulating L-FABP expression in two approaches. First, L-FABP content was more than doubled upon treating the cells with the potent peroxisome proliferators bezafibrate and Wy14,643 and incubation of these cells with [1-14C]oleic acid led to an increase in fatty acid uptake rate from 0.55 to 0.74 and 0.98 nmol/min per mg protein, respectively. In the second approach L-FABP expression was reduced by stable transfection with antisense L-FABP mRNA yielding seven clones with L-FABP contents ranging from 0.03% to 0.14% of cytosolic proteins. This reduction to one sixth of normal L-FABP content reduced the rate of [1-14C]oleic acid uptake from 0.55 to 0. 19 nmol/min per mg protein, i.e., by 66%. The analysis of peroxisome proliferator-treated cells and L-FABP mRNA antisense clones revealed a direct correlation between L-FABP content and fatty acid uptake.  (+info)

*Hepatocellular carcinoma

... transform into the more dangerous hepatocellular carcinoma. Hepatocellular carcinoma, like any other cancer, develops when ... Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the most common cause of death ... The risk of hepatocellular carcinoma in type 2 diabetics is greater (from 2.5 to 7.1 times the non diabetic risk) depending on ... Since hepatitis B or C is one of the main causes of hepatocellular carcinoma, prevention of this infection is key to then ...

*Fibrolamellar hepatocellular carcinoma

... (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young ... Lafaro KJ, Pawlik TM (2015) Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma 2:151 ... The name fibrolamellar hepatocellular carcinoma was coined by Craig et al. in 1980. It was not recognised as distinct form of ... 2009). "Fibrolamellar hepatocellular carcinoma- report of a case". Chang Gung Med J. 32 (3): 336-9. PMID 19527614. ...

*Hepatitis B

This population has a 40% lifetime risk of death from cirrhosis or hepatocellular carcinoma. Of those infected between the age ... This type of infection dramatically increases the incidence of hepatocellular carcinoma (HCC; liver cancer). Across Europe, ... El-Serag HB (22 September 2011). "Hepatocellular carcinoma". New England Journal of Medicine. 365 (12): 1118-27. doi:10.1056/ ... El-Serag HB, Rudolph KL (June 2007). "Hepatocellular carcinoma: epidemiology and molecular carcinogenesis". Gastroenterology. ...

*Long-term effects of alcohol consumption

Morgan TR, Mandayam S, Jamal MM (November 2004). "Alcohol and hepatocellular carcinoma". Gastroenterology. 127 (5 Suppl 1): S87 ... Voigt MD (February 2005). "Alcohol in hepatocellular cancer". Clin Liver Dis. 9 (1): 151-69. doi:10.1016/j.cld.2004.10.003. ...

*Cancer biomarkers

Behne, Tara; Copur, M. Sitki (1 January 2012). "Biomarkers for Hepatocellular Carcinoma". International Journal of Hepatology. ... a marker indicating a patient's non-small-cell lung carcinoma (NSCLC) will likely respond to gefitinib or erlotinib treatment. ... "Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma". Journal of ... Non-small-cell lung carcinoma), HER-2 (Breast Cancer), KIT (Gastrointestinal stromal tumor), PSA (Prostate Specific Antigen) ( ...

*Glypican

Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT (April 2008). "Biology of hepatocellular carcinoma". Annals of ... Abnormal expression of glypicans has been noted in multiple types of cancer, including human hepatocellular carcinoma, ovarian ... while GPC3 expression occurs in the majority of human hepatocellular carcinomas. A similar correlation has been found in ...

*Liver cancer

"Overview of Hepatocellular Carcinoma". Liver Cancer. Archived from the original on 18 March 2017. Retrieved 18 March 2017. " ... Hepatocellular carcinoma is associated with abdominal mass, abdominal pain, emesis, anemia, back pain, jaundice, itching, ... Zhao YJ, Ju Q, Li GC (2013). "Tumor markers for hepatocellular carcinoma". Mol Clin Oncol. 1 (4): 593-598. doi:10.3892/mco. ... Kew, MC (March 2013). "Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an ...

*Timeline of liver cancer

"Hepatocellular Carcinoma (Liver Cancer)". Retrieved 30 September 2016. "Risk Factors for the Rising Rates of Primary Liver ... "Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication". Cancer. 36: 1250-1257. doi:10.1002/1097-0142 ... "Helicobacter pylori and Liver - Detection of Bacteria in Liver Tissue from Patients with Hepatocellular Carcinoma Using Laser ... "Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat ...

*Iron overload

... increases the risk of hepatocellular carcinoma. This risk is greater in those with cirrhosis but is still present ... Kowdley, KV (November 2004). "Iron, hemochromatosis, and hepatocellular carcinoma". Gastroenterology. 127 (5 Suppl 1): S79-86. ...

*Paul W. Ewald

Michielsen, Peter P; Francque, Sven M; Van Dongen, Jurgen L (2005). "Viral hepatitis and hepatocellular carcinoma". World ...

*Mallory body

Mallory bodies in hepatocellular carcinoma. Trichrome stain. "Cell Injury". Denk, H; Franke, WW; Eckerstorfer, R; Schmid, E; ... hepatocellular carcinoma (23%) and morbid obesity (8%), among other conditions. However, it has also been reported in certain ...

*Bland embolization

The rationale for the use of bland embolization for hepatocellular carcinoma(HCC) and/or other hyper-vascular tumors is based ... The most common indication of this therapy is for treatment of unresectable primary hepatocellular carcinoma, based on anatomic ... Llovet JM, Brú C, Bruix J (1999). "Prognosis of hepatocellular carcinoma: the BCLC staging classification". Seminars in Liver ... Shah RP, Brown KT, Sofocleous CT (October 2011). "Arterially directed therapies for hepatocellular carcinoma". AJR. American ...

*Infections associated with diseases

Michielsen, Peter P; Francque, Sven M; Van Dongen, Jurgen L (2005). "Viral hepatitis and hepatocellular carcinoma". World ... H Salim, Omer E; Hamid, Hytham K S; Mekki, Salwa O; Suleiman, Suleiman H; Ibrahim, Shakir Z (2010). "Colorectal carcinoma ... February 2012). "Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma". Genome Research. 22 (2): 299- ...

*Liver tumor

Zhao YJ, Ju Q, Li GC (2013). "Tumor markers for hepatocellular carcinoma". Mol Clin Oncol. 1 (4): 593-598. doi:10.3892/mco. ... The most frequent, malignant, primary liver cancer is hepatocellular carcinoma (HCC, also named hepatoma, which is a misnomer ... For the most common of these, hepatocellular carcinoma (HCC), these include sonography (ultrasound), computed tomography (CT) ... hepatocellular carcinoma, hepatic adenoma, follicular nodular hyperplasia (FNH), and hypervascular metastasis), but may be ...

*Santosh G. Honavar

Orbital metastasis from hepatocellular carcinoma. Surv Ophthalmol. 2005 Sep-Oct;50(5):485-9. 133. Murthy R, Honavar SG, ... Primary adenoid cystic carcinoma: an extremely rare eyelid tumor. Ophthal Plast Reconstr Surg. 2012 Mar-Apr;28(2):e35-6. 84. ... Adenoid cystic carcinoma of the lacrimal gland: role of nuclear survivin (BIRC5) as a prognostic marker. Histopathology. 2013 ... Basal cell carcinoma of the eyelid associated with Gorlin-Goltz syndrome. Ophthalmology. 2001 Jun;108(6):1115-23. 181. Honavar ...

*R. Palmer Beasley

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981;2(8256):1129-1133 " ... His longitudinal observations were the first to demonstrate that hepatocellular carcinoma was prevented in Taiwanese males by ... making hepatocellular carcinoma and cirrhosis of the liver--one of the primary causes of death for much of the developing world ... cirrhosis and hepatocellular carcinoma." Dr. Beasley "demonstrated the efficacy of hepatitis B immune globulin in blocking ...

*Hep G2

2015). "Poly(vinyl alcohol)/gelatin Hydrogels Cultured with HepG2 Cells as a 3D Model of Hepatocellular Carcinoma: A ... Fanelli, Alex (2016). "HepG2 (liver hepatocellular carcinoma): cell culture". Retrieved 3 December 2017. Mersch-Sundermann, V ... was derived from the liver tissue of a 15-year-old Caucasian American male with a well-differentiated hepatocellular carcinoma ...

*Oncovirus

Although this agent was the clear cause of hepatitis and might contribute to liver cancer hepatocellular carcinoma, this link ... Beasley RP, Hwang LY, Lin CC, Chien CS (November 1981). "Hepatocellular carcinoma and hepatitis B virus. A prospective study of ... The hepatitis B vaccine is the first vaccine that has been established to prevent cancer (hepatocellular carcinoma) by ... HCV was subsequently shown to be a major contributor to liver cancer (hepatocellular carcinoma) worldwide. 1994: Patrick S. ...

*Michael Houghton (virologist)

"Hepatitis C virus infection is associated with the development of hepatocellular carcinoma". Proc. Natl. Acad. Sci. USA. 87: ... "Hepatitis C HCV associated hepatocellular carcinoma". Hepatology. 10: 580. doi:10.1002/hep.1840100432. De Bisceglie, AM; Alter ...

*Interventional oncology

Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013 Jun;11(6):604-11; quiz ... primary liver tumours known as hepatocellular carcinoma and liver metastases. Lung cancer: usually lung metastases or ... Kidney Cancer: usually small kidney tumours known as renal cell carcinoma. Bone Cancer: for bone metastases located in the ...

*Alcohol and cancer

A study of the influence of alcohol intake on tumor growth of hepatocellular carcinoma (HCC) in patients with type C cirrhosis ... Matsuhashi T, Yamada N, Shinzawa H, Takahashi T (June 1996). "Effect of alcohol on tumor growth of hepatocellular carcinoma ... September 1997). "Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in ... April 2006). "Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy". Cancer ...

*Aflatoxin B1

Prevalence of hepatocellular carcinoma in individuals exposed to aflatoxin, increases with co-infection of hepatitus B virus. ... Aflatoxin B1 is considered the most toxic aflatoxin and it is highly implicated in hepatocellular carcinoma (HCC) in humans. In ... Kew, MC (September 2013). "Aflatoxins as a cause of hepatocellular carcinoma". Journal of Gastrointestinal and Liver Diseases. ... and those with the bio-markers and infected with hepatitis B virus were at a 60 times greater risk for hepatocellular carcinoma ...

*Reptilase time

Johnson PJ, White Y, Woolf IL, Williams R (October 1977). "Reptilase time in cirrhosis and hepatocellular carcinoma". Br Med J ...

*SALL4

... hepatocellular carcinoma (HCC), lung cancer, and glioma. In many of these cancers, SALL4 expression was compared in tumor cells ... "Oncofetal gene SALL4 in aggressive hepatocellular carcinoma". The New England Journal of Medicine. 368 (24): 2266-76. doi: ... colorectal carcinoma, and esophageal squamous cell carcinoma. It is unclear how SALL4 expression is de-regulated in malignant ... twist and maml genes in esophageal squamous cell carcinoma". Int J Pharm Sci Res. 8 (7): 1000-07. doi:10.13040/IJPSR.0975- ...

*TUC338

Page for TUC338 at Rfam Yam JW, Wong CM, Ng IO (2010-01-01). "Molecular and functional genetics of hepatocellular carcinoma". ... Expression of this RNA gene has been found to dramatically increase in hepatocellular carcinoma (HCC) cells. The TUC338 RNA ... "Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma". ...

*Badri Nath Tandon

... and virological characteristics of hepatocellular carcinoma in Asia: Survey of 414 patients from four countries". Journal of ...
Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of primary liver cancer. Fibrolamellar hepatocellular carcinoma was first described Edmondson in 1956.[1][2] Fibrolamellar hepatocellular carcinoma is most commonly seen in children and young adults. The pathogenesis of fibrolamellar hepatocellular carcinoma is characterized by the lack of cirrhosis. Common causes of fibrolamellar hepatocellular carcinoma, include: active hepatic inflammation, hepatitis B or C viral infection, alcohol-related liver disease, nonalcoholic fatty liver disease, and dietary aflatoxin B1. The majority of patients with fibrolamellar hepatocellular carcinoma remain asymptomatic for years. Early clinical features include abdominal pain, weight loss, and malaise. If left untreated, the majority of patients with fibrolamellar hepatocellular carcinoma may progress to develop metastasis to abdominal lymph nodes, peritoneum, and lung. Common complications of fibrolamellar hepatocellular carcinoma include: hepatic ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Hepatocellular Carcinoma (HCC) market report covers research informatics related to Metastatic Hepatocellular Carcinoma (HCC) clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Hepatocellular Carcinoma (HCC) clinical trials and for research professionals.. The report, "Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Hepatocellular Carcinoma (HCC) clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), ...
Gehring, A.J., Ho, Z.Z., Tan, A.T., Bertoletti, A., Aung, M.O., Lim, S.G., Lee, K.H., Tan, K.C., Lim, S.G. (2009). Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. Gastroenterology 137 (2) : 682-690. [email protected] Repository. https://doi.org/10.1053/j.gastro.2009.04. ...
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young adults and is characterized, under the microscope, by laminated fibrous layers interspersed between the tumour cells. Approximately 200 new cases are diagnosed worldwide each year. A recent study showed the presence of the DNAJB1-PRKACA chimeric transcript (resulting from a 400kb somatic deletion on chromosome 19) in 100% of the FHCCs examined (15/15) This gene fusion has been confirmed in a second study. The histopathology of FHCC is characterized by laminated fibrous layers, interspersed between the tumor cells. Cytologically, the tumor cells have a low nuclear to cytoplasmic ratio with abundant eosinophilic cytoplasm. Tumors are non-encapsulated, but well circumscribed, when compared to conventional HCC (which typically has an invasive border). Due to lack of symptoms, until the tumor is sizable, this form of cancer is often advanced when diagnosed. Symptoms include ...
Sigma-Aldrich offers abstracts and full-text articles by [Seung In Seo, Hyoung Su Kim, Won Jin Kim, Woon Geon Shin, Doo Jin Kim, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Joo Seop Kim, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park].
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
It has been estimated that 70% to 90% of patients with hepatocellular carcinomas have an established background of chronic liver disease or cirrhosis, the major causes of which are HBV or HCV infection (26, 27). More than 50% (340,000 cases) of all hepatocellular carcinomas worldwide are associated with HBV infection and near 30% (195,000 cases) are HCV infection-related (28, 29). Once cirrhosis is established, the annual risk of developing hepatocellular carcinoma is estimated to be as high as 3% to 4% (30). Screening for hepatocellular carcinoma using serum AFP or combined with ultrasonography in these high-risk populations is still the essential way for detection and diagnosis of hepatocellular carcinomas at an earlier stage, when curative therapies are likely to be more successful (31, 32).. On the basis of the specific screening requirements for hepatocellular carcinomas in the context of chronic liver disease and cirrhosis and the general criteria for an adequate screening test to detect ...
To the editor: We are writing in response to the letter (1) on fibrolamellar hepatocellular carcinoma, in which Ruffin points out that the cases of this tumor reported since 1941 have all originated in the United States. We report two cases of this tumor diagnosed in patients treated at our hospital.. A 25-year-old man was hospitalized for epigastric discomfort; anorexia was present for 5 months. Physical examination showed a liver edge 12 cm below the right costal margin. The erythrocyte sedimentation rate was 135 mm/h; alkaline phosphatase, 100 U/L (normal, ≤ 40 U/L); and gamma-glutamyltransferase, 89 IU/L (normal, ≤ 30 ...
AIM: To investigate the antitumor effects of cytosine deaminase (CD) gene in combination with prodrug flucytosine (Flu, 5-fluorocytosine) on human hepatocellular carcinoma. METHODS: CD gene was transduced into human hepatocellular carcinoma cell line
TY - JOUR. T1 - Altered findings of hepatic arteriography after radiofrequency ablation of hepatocellular carcinoma. T2 - Comparison of pre-ablation and post-ablation angiograms. AU - Kim, Byung Moon. AU - Cho, Jae Hyun. AU - Won, Je Hwan. AU - Lee, Do Yun. AU - Lee, Jong Tae. AU - Kim, Hyun Cheol. AU - Park, Sung Il. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Objective: To evaluate the altered findings of hepatic arteriography after radiofrequency (RF) ablation of hepatocellular carcinoma which can potentially influence subsequent transcatheter arterial chemoembolization. Materials and methods: Hepatic arteriograms of 26 index hepatocellular carcinomas in 24 patients treated only by RF ablation (M:F = 22:2, mean age 55 years), in which hepatic arteriography was performed before and after RF ablation, were retrospectively compared for the altered findings. Results: The altered findings of hepatic arteriography after RF ablation of the hepatocellular carcinoma were arterio-portal shunt (n = 3), ...
Many chemotherapeutic agents have been successfully used to treat hepatocellular carcinoma (HCC);however, the development of chemoresistance in liver cancer cells usually results in a relapse and worseningof prognosis. It has been demonstrated that DNA methylation and histone modification play crucial roles inchemotherapy resistance. Currently, extensive research has shown that there is another potential mechanismof gene expression control, which is mediated through the function of short noncoding RNAs, especially formicroRNAs (miRNAs), but little is known about their roles in cancer cell drug resistance. In present study, bytaking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, ithas been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/CDDP (cisplatin) cells, compared with parental HepG2 cells. Bioinformatics analysis and luciferase assays ofNrf2-3-untranslated region-based reporter constructor
TY - JOUR. T1 - Lipocalin-2 Induces Apoptosis in Human Hepatocellular Carcinoma Cells Through Activation of Mitochondria Pathways. AU - Chien, Ming Hsien. AU - Ying, Tsung Ho. AU - Yang, Shun Fa. AU - Yu, Ji Kuen. AU - Hsu, Chih Wei. AU - Hsieh, Shu Ching. AU - Hsieh, Yi Hsien. PY - 2012. Y1 - 2012. N2 - Lipocalin 2 (LCN2) is a secreted, iron-binding glycoprotein that is abnormally expressed in some malignant human cancers. However, the roles of LCN2 in hepatocellular carcinoma (HCC) cells are unknown. In this study, we suggested the LCN2 and LCN2R were weak detected in the HCC cell lines, LCN2 and LCN2R were found to be down-regulated in tumor tissues in 16 HCC patients. MTT, DAPI, TUNEL, and flow cytometry analyses revealed that LCN2 overexpression dramatically inhibited cell viability, induced apoptosis features of cell-cycle arrest in sub-G1 phase, in DNA fragmentation, and in condensation of chromatin in Huh-7 and SK-Hep-1 cells. Western blots were used to detect the activation of caspase, ...
Hepatocellular carcinoma (HCC) is a serious consequence of persistent hepatitis C virus (HCV) infection and represents one of the most aggressive neoplasms globally. The implication of microRNA-301...
HCC is the third most common cancer worldwide, causing about 700,000 deaths annually.2 It is associated with cirrhosis, hepatitis B and C virus, primary biliary and sclerosing cholangitis, aflatoxins, and autoimmune hepatitis.2,3 Extrahepatic metastatic HCC, as observed in this case, occur in 30-50% of HCC patients; the most common sites are lungs, bones, adrenal glands, and lymph nodes.4 Rare and unusual metastatic sites have been described in the literature, including the chest wall presenting as a breast mass and metastasis to the nasal septum.5,6 Indeed, extrahepatic metastases to the humeral shoulder, chest wall, and bony lesions are exceedingly rare, as only a handful of cases have been reported.3,7 Traditionally, a few systems have been widely employed for HCC staging (e.g. Okuda, tumor/node/metastasis), however, newer classification systems that take into account prognostication and treatment regimens are increasingly being utilized.8 The Cancer of the Liver Italian Program (CLIP) and ...
TY - JOUR. T1 - Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. AU - Yoon, Eileen L.. AU - Yeon, Jong Eun. AU - Lee, Hyun Jung. AU - Suh, Sang Jun. AU - Lee, Sun Jae. AU - Kang, Seong Hee. AU - Kang, Keunhee. AU - Yoo, Yang Jae. AU - Kim, Ji Hoon. AU - Yim, Hyung Joon. AU - Byun, Kwan Soo. PY - 2014/3/1. Y1 - 2014/3/1. N2 - GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these ...
TY - JOUR. T1 - Recurrent hepatocellular carcinoma after liver transplant. T2 - Identifying the high-risk patient. AU - Nissen, Nicholas N.. AU - Menon, Vijay. AU - Bresee, Catherine. AU - Tran, Tram T.. AU - Annamalai, Alagappan. AU - Poordad, Fred. AU - Fair, Jeffrey H.. AU - Klein, Andrew S.. AU - Boland, Brendan. AU - Colquhoun, Steven D. PY - 2011/1/1. Y1 - 2011/1/1. N2 - Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Hepatocellular carcinoma tissue array, 63 cases_63 cores, replaced by LV809 \ BS03014 for more molecular products just contact us
Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma ...
Background To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis.
We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment. A 74-year-old man with diabetes mellitus and hypertension was diagnosed with hepatocellular carcinoma associated with fatty liver. Three weeks after sorafenib therapy, at Eastern Cooperative Oncology Group performance status 3, he developed jaundice, general weakness, flapping tremor, nausea, and anorexia. Sorafenib was stopped: laboratory tests showed a relevant elevation of transaminases suggesting diagnosis of acute hepatitis. During hospital admission, the patient died of liver failure. Sorafenib is the first successful target therapy effective for advanced hepatocellular carcinoma. The most common adverse events are fatigue, hand-foot skin reaction, skin rash/desquamation, diarrhea, and hypertension, whereas liver dysfunction is uncommon. To our knowledge, this is the first patient reported in the literature with hepatocellular ...
TY - JOUR. T1 - Surgical Resection vs. Ablative Therapies Through a Laparoscopic Approach for Hepatocellular Carcinoma: a Comparative Study. AU - Santambrogio, Roberto. AU - Santambrogio, Roberto. AU - Barabino, Matteo. AU - Bruno, Savino. AU - Mariani, Nicolò. AU - Maroni, Nirvana. AU - Bertolini, Emanuela. AU - Franceschelli, Giuseppe. AU - Opocher, Enrico. PY - 2017/12/12. Y1 - 2017/12/12. N2 - © 2017 The Society for Surgery of the Alimentary Tract Background: When compatible with the liver functional reserve, laparoscopic hepatic resection remains the treatment of choice for hepatocellular carcinoma while laparoscopic ablation therapies appear as a promising less invasive alternative. The aim of the study is to compare two homogeneous groups of patients submitted to either hepatic resection or thermoablation for the treatment of single hepatocellular carcinoma (≤ 3 cm). Methods: We enrolled 264 cirrhotic patients out of 905 cases consecutively evaluated for hepatocellular carcinoma. We ...
TY - JOUR. T1 - An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. AU - Bimonte, Sabrina. AU - Barbieri, Antonio. AU - Palaia, Raffaele. AU - Leongito, Maddalena. AU - Albino, Vittorio. AU - Piccirillo, Mauro. AU - Arra, Claudio. AU - Izzo, Francesco. PY - 2015/3/9. Y1 - 2015/3/9. N2 - Hepatocellular carcinoma is a highly aggressive malignancy and is the third leading cause of cancer-related deaths worldwide. Although surgery is currently considered the most effective curative treatment for this type of cancer, it is note that most of patients have a poor prognosis due to chemioresistence and tumor recurrence. Loco-regional therapies, including radiofrequency ablation, surgical resection and transcatheter arterial chemoembolization play a major role in the clinical management of hepatocellular carcinoma. In order to improve the treatment outcome of patients diagnosed with this disease, several in vivo studies by using different techniques on cancer ...
1. Patel M, Shariff M I, Ladep N G. et al. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract. 2012;18:335-42 2. Padhya K T, Marrero J A, Singal A G. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-92 3. Schoenleber S J, Kurtz D M, Talwalkar J A, Roberts L R, Gores G J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385-92 4. Miura S, Mitsuhashi N, Shimizu H. et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56 5. Lassalle P, Molet S, Janin A. et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458-64 6. Bechard D, Meignin V, Scherpereel A. et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal ...
Background and aims. Information on the impact of therapeutic strategies of hepatocellular carcinoma is still incomplete due to the lack of surveys involving primary-care centres. Patients and methods. The Gruppo Epatologico Lombardo (GEL) carried out a study on 361 incident hepatocellular carcinoma observed from January to December 1998 in 22 hospitals in Lombardy. The clinical, pathological and therapeutic data were collected from all patients; 5-year survival and factors related to outcome were analysed. Results. Two hundred and ninety-seven patients were male (M[F: 4.6/1, mean age 66); 61% were HCV-pos, 15% HBV-pos, 17% alcoholic. Cirrhosis was present in 333 (92%) and was classified as Child-A in 197 (59%), Child-B in 85 (26%) and Child-C in 51 (15%) cases. Hepatocellular carcinoma was multifocal/diffuse (more than three nodules) in 91 (25%), less than three nodules in 86 (24%) and monofocal in 184 (51 %) (,= 3 cm in 146). As to the therapy: 145 hepatocellular carcinomas (40%) were ...
RESULTS: Seven patients (median age 21 years, range 19 - 42, 5 men, 2 women) underwent surgery for FLC. No patient had underlying liver disease or an elevated alpha feto-protein (AFP) at either initial presentation or recurrence. Six patients had a solitary tumour at diagnosis (mean largest diameter = 12cm), and underwent left hepatectomy (N=2), right hepatectomy (N=1), extended right hepatectomy (N=1), and segmentectomies (N=2). Three patients underwent a portal lymphadenectomy for regional lymphatic tumour involvement. One patient with advanced extrahepatic portal nodal metastasis was unresectable. No peri-operative deaths occurred. Recurrence occurred post resection in all 6 patients. Median overall survival was 60 months, and overall 5-year survival was 4 out of 7 (57%). Post-resection survival (N=6) was 61 months, with a 5-year survival rate of 4 out of 6 (67%). The patient with unresectable disease survived 38 months after tumour embolisation with Lipiodol ...
Fibrolamellar hepatocellular carcinoma (FL-HCC) is generally a fairly rare event in routine pathology practice. This variant of hepatocellular carcinoma (HCC) is peculiarly intriguing and,in addition, poorly understood. Young people or children are often the target individuals with this type of cancer. Previously, I highlighted some pathology aspects of FL-HCC, but in this review, the distinctive clinico-pathologic features of FL-HCC and the diagnostic pathologic criteria of FL-HCC are fractionally reviewed and expanded upon. Further, molecular genetics update data with reference to this specific tumor are particularly highlighted as a primer for general pathologists and pediatric histopathologists. FL-HCC may present with metastases, and regional lymph nodes may be sites of metastatic spread. However, peritoneal and pulmonary metastatic foci have also been reported. To the best of our knowledge, FL-HCC was initially considered having an indolent course, but survival outcomes have recently been updated
CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens
We read with interest the article by Bruix et al1 in which Sorafenib was regarded as the standard treatment for hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT). However, Sorafenib can only confer 2-3 months of overall survival (OS) benefit2 ,3 and is inapplicable to many patients due to extensive side effects and high price. Zhong et al4 proposed that liver resection might provide survival benefit to patients with HCC-PVTT with adequate liver function. However, this proposal was based on literature survey, lacked definite patient inclusion criteria and failed to provide information on patients baseline characteristics. Therefore, explorations of alternative therapeutics for patients with HCC-PVTT are still needed.. Although not recommended by mainstream guidelines5 ,6 for patients with HCC-PVTT, transarterial chemoembolisation (TACE) has long been practiced in the clinic in selected patients with HCC-PVTT.7 ,8 Gamma knife surgery (GKS) has shown favourable ...
BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative ...
TY - JOUR. T1 - Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. AU - Chang, Te Sheng. AU - Wu, Yu Chih. AU - Tung, Shui Yi. AU - Wei, Kuo Liang. AU - Hsieh, Yung Yu. AU - Huang, Hao Chun. AU - Chen, Wei Ming. AU - Shen, Chien Heng. AU - Lu, Chang Hsien. AU - Wu, Cheng Shyong. AU - Tsai, Ying Huang. AU - Huang, Yen Hua. PY - 2015/6/10. Y1 - 2015/6/10. N2 - Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC), and all liver study societies recommend HCC surveillance in patients with cirrhosis. However, no ideal modality for HCC surveillance has been determined. The aim of this study is to assess the effectiveness of α-fetoprotein (AFP) measurement in HCC surveillance.METHODS:In this retrospective analysis, all patients with cirrhosis, who received HCC surveillance through ultrasound (US) and AFP measurement between January 2002 and July 2010, were followed up until June 2013. The performance effectiveness of ...
Conference Paper: Pathway analysis of genome-wide association data on hepatocellular carcinoma in southern Chinese patients with chronic hepatitis B virus ...
Sigma-Aldrich offers abstracts and full-text articles by [Gek San Tan, Kiat Hon Lim, Hwee Tong Tan, May Lee Khoo, Sze Huey Tan, Han Chong Toh, Maxey Ching Ming Chung].
Objective: To investigate the prognostic relationship between the expression levels of periostin (POSTN) in hepatocellular carcinoma (HCC) tissues as well as its effect in invasion and metastasis. Methods: The expression levels of POSTN in liver cancer tissues were detected with real-time quantitative PCR (QPCR) and immunohistochemistry (IHC). Kaplan-Meier method and Log-rank test were used to analyze the relationship between POSTN expression level and postoperative prognosis in patients with liver cancer. The expression of POSTN in hepatocellular carcinoma cells with different metastasis characteristics were detected in vitro and the overexpression of POSTN in low metastatic hepatocellular carcinoma cells was mediated through plasmid transfection techniques. The effects of POSTN on invasion and metastasis of hepatocellular carcinoma cells were determined by transwell migration and matrigel invasion assay. The comparative expression level of POSTN was analyzed by t-test. Results: The expression ...
MODULATOR IMPACTS OF PROPOLIS EXTRACT AGAINST DOXORUBICIN MEDIATED CARCINOGENESIS ON HEPATOCELLULAR CARCINOMA AND Drosophila SOMATIC CELLS
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients present with intermediate or advanced disease. Percutaneous ethanol injection, radiofrequency ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a curative treatment and have achieved very limited success in eradicating large HCC. With the development of new radiotherapy (RT) technique, RT can be more safely given to patients with larger tumor burden. Thus, TACE combined with RT has been suggested for treating large HCC. Based on the results of these studies, RT could achieve a tumor response rate of 50 % to 70 %. However, it has not been definitively shown to prolong the overall or disease-free survival due to lack of a phase III clinical trial. In contrast, a retrospective clinical investigation with molecular study suggests that sublethal dose of RT promoted HCC growth outside RT field.. Two phase III trials were shown to be efficacious and well-tolerated in patients ...
We read with interest the article by Wang et al1 on zinc-finger protein 545 (ZNF545) acting as a tumour suppressor gene (TSG) in gastric cancer by inhibiting rRNA transcription and its methylation as a prognostic factor for early stages of gastric cancer. Inactivation of TSGs through promoter hypermethylation also plays an important role in progression of hepatocellular carcinoma (HCC).2-4 We wish to report the results of the expression profile and epigenetic regulation of ZNF545 in HCC, and its methylation role on early-stage HCC progression after thermal ablation.. Our results showed reduced or loss of ZNF545 expression was found in seven human hepatic cancer cell lines, including SMMC7721, PRF/PCL-5, SK-hep1, HepG2, BEL7402, LAM3 and SNU449, by semiquantitative reverse transcription PCR. Expression of ZNF545 was detected in another cell of HBXF344. The methylation status of the ZNF545 promoter was examined by methylation-specific PCR (MSP). Complete methylation of the ...
Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein Marine Gilabert,1,2 Jean-Luc Raoul3 1Department of Medical Oncology, Paoli-Calmettes Institute, 13232 Marseille Cedex 9, France; 2Centre de Recherche en Cancérologie de Marseille, Stress Cell Unit, Institut National de la Sante et de la Recherche Medicale 1068, Aix-Marseille University, Cedex 8, Marseille, France; 3Department of Medical Oncology, Institut de Cancérologie de l’Ouest René Gauducheau, 44805 Nantes, France Abstract: Hepatocellular carcinoma (HCC) represents ~90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first- and second-line treatment. This study focused on the efficacy of antiangiogenics in
TY - JOUR. T1 - Roles of ethnicity in survival of hepatocellular carcinoma patients in Malaysia. AU - Mohammed Nawi, Azmawati. AU - Krisnan, R.. PY - 2012. Y1 - 2012. N2 - The incidence of hepatocellular carcinoma (HCC) in Malaysia for the year 2001 was 2.8 per 100,000 people. The mortality rate is increasing. A retrospective cohort study measuring the survival of HCC patients who received treatment in Selayang Hospital was conducted from 1 January 2003 to 31 December 2006. The main objectives of the study were to measure the survival of the patients and to understand the influencing factors, especially ethnicity. The subjects were newly diagnosed cases of HCC by CT scan and histopathological assessment who underwent futher investigations and treatments in Hospital Selayang (inception cohort). The survival time was measured from the date of diagnosis until the subjects died, or failed to follow-up at the end of the study period (31 December 2007). A total of 299 patients were selected with 95 ...
Cell culture. Human hepatocellular carcinoma cell line (Hep3B), human colorectal carcinoma cell line (SW620), and human normal lung fibroblast cell lines (NHLF and MRC5) were obtained from the American Type Culture Collection. Human hepatocellular carcinoma cell lines (BEL7404 and SMMC7721) and human normal liver cell lines (QSG7701 and L-02) were purchased from the Shanghai Cell Collection. HEK293 was obtained from Microbix Biosystems, Inc. Cells were maintained in humidified 37°C atmosphere containing 5% CO2 and cultured in DMEM (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 4 mmol/L glutamine, 50 units/mL penicillin, and 50 μg/mL streptomycin.. Virus construction and production. The constructs including pCN205-EGFP and pCN205-IL-24 were generated according to the standard molecular cloning protocol. The homologous recombination between pCN205-EGFP and pCN205-IL-24 plasmids and pCN103 plasmid carrying oncolytic adenoviral backbone was done ...
Systemic chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). Before the introduction of sorafenib, cytotoxic agents, hormonal therapies, or many combinations of these were the mainly used modalities for systemic chemotherapy of advanced HCC. However, such regimens were of only limited value in clinical practice, because some randomized controlled studies comparing promising regimens with no treatment or doxorubicin alone failed to show any overall survival advantage. In two pivotal phase III placebo-controlled studies, the SHARP trial and the Asia-Pacific trial, sorafenib was demonstrated to significantly delay the time to progression and the overall survival time in patients with advanced HCC. Therefore, sorafenib therapy has come to be acknowledged as a standard therapy for advanced HCC worldwide. After the introduction of sorafenib, a number of phase III trials of various molecular-targeted agents vs. sorafenib as first-line chemotherapy and of
The herbal extract Benja‑ummarit (BU) is a traditional Thai medicine with a putative cancer‑suppressing effect. However, this effect has only been tested in vitro in human hepatocarcinoma cell lines. The present study determined the efficacy of a BU extract to treat hepatocellular carcinoma (HCC) in rats in vivo and established its anti‑angiogenic and anti‑proliferative properties. The BU extract was prepared in 95% ethanol and its composition determined using liquid chromatography‑mass spectrometry. HCC was induced in Wistar rats by an injection of diethylnitrosamine (DEN), followed 2 weeks later by injections of thioacetamide (TAA) thrice weekly for 4 weeks. Following 2 months, the DEN‑TAA‑treated rats were divided into 6 groups that were treated orally for another 2 months with: i) No treatment; ii) vehicle; iii) 30 mg/kg sorafenib (SF); iv) 1 mg/kg BU; v) 10 mg/kg BU; or vi) 50 mg/kg BU. Liver samples were collected for gross morphological, histological, reverse ...
TY - JOUR. T1 - Promoter-independent loss of mRNA and protein of the Rb gene in a human hepatocellular carcinoma. AU - Hada, Hajime. AU - Koide, Norio. AU - Morita, Takechiyo. AU - Shiraha, Hidenori. AU - Shinji, Toshiyuki. AU - Nakamura, Masaki. AU - Ujike, Kouzo. AU - Takayama, Niro. AU - Oka, Takahiko. AU - Hanafusa, Tadashi. AU - Yumoto, Yasuhiro. AU - Hamazaki, Keisuke. AU - Tsuji, Takao. PY - 1996. Y1 - 1996. N2 - Background: Inactivation of the retinoblastoma (Rb) gene is considered to play a fundamental role in the genesis and progression of several human cancers. In retinoblastoma, the inactivation of Rb promoter by mutations or hypermethylation has been reported. Although genetic changes of Rb gene have been described in hepatocellular carcinoma (HCC), an epigenetic change such as hypermethylation of the Rb promoter as reported in retinoblastoma has not been described. Materials and Methods: We examined the hypermethylation in the promoter region of Rb gene by restriction fragment ...
In most cases, hepatocellular carcinoma develops in patients with chronic liver disease (70-90% of all patients). More about Hepatocellular Carcinoma
Background. Transarterial chemoembolization alone or in association with radiofrequency ablation is an effective bridging strategy for patients with hepatocellular carcinoma awaiting for a liver transplant.However, cost of this therapymay limit its utilization. This study was designed to evaluate the outcomes of a protocol involving transarterial embolization, percutaneous ethanol injection, or both methods for bridging hepatocellular carcinomas prior to liver transplantation. Methods. Retrospective review of all consecutive adult patients who underwent a first liver transplant as a treatment to hepatitis C-related hepatocellular carcinoma at our institution between 2002 and 2012. Primary endpoint was patient survival. Secondary endpoint was complete tumor necrosis. Results. Forty patients were analyzed, age 58 ± 7 years.There were 23 males (57.5%). Thirty-six (90%) out of the total 40 patients were within Milan criteria. Complete necrosis was achieved in 19 patients (47.5%). One-, 3-, and ...
The monoclonal antibody AF-20 was raised against the human hepatocellular carcinoma (HCC) cell line FOCUS and binds with high affinity to a rapidly internalized 180-kd homodimeric glycoprotein that is abundantly expressed on the surface of human HCC and other human cancer cell lines. Immunoliposomes were produced by covalently coupling AF-20 to liposomes containing carboxyfluorescein. Interaction of immunoliposomes with various HCC cell lines in vitro was quantitatively assessed by flow cytometry and qualitatively analyzed by fluorescence microscopy. Liposomes bearing an isotype-matched nonrelevant monoclonal antibody (MAb) and cell lines not expressing AF-20 antigen served as controls. AF-20-immunoliposomes specifically bound to HCC and other human cancer cell lines expressing the AF-20 antigen and were rapidly internalized at 37 degrees C. Interaction of AF-20-conjugated liposomes with these cell lines was between 5 and 200 times greater than that of unconjugated liposomes, whereas no difference was
High viral load is an independent risk factor for development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Antiviral therapy can reduce but not eliminate the risk of HCC. The aim of this study was to identify the risk factors for HCC development in CHB patients during antiviral therapy.CHB patients with HBV DNA level ≥10 copies/mL, with or without compensated cirrhosis receiving adefovir were followed up every 6 months for 10 years (2004-2014). The primary endpoint was the development of HCC. The cumulative incidence and risk factors of HCC were evaluated by the Kaplan-Meier method and multivariate Cox proportional hazards models.At baseline, 28 of the 120 patients (23.3%) were cirrhotic. One patient developed HCC within 1 year, and therefore 119 patients were analyzed. At the end-point of follow-up, 59.7% (71/119) patients achieved virological remission (VR). Overall, 16 patients developed HCC, giving a 10-year cumulative incidence of 15.73%. Multivariate ...
Neovascularization provides the route for nutrient supply to the tumor and the conduit for tumor cells to be shed into the circulation. CD31 is a pan-endothelial cell marker and CD105 is an active endothelial cell marker, but whether there is a link between CD105 expression and metastasis in Hepatocellular carcinoma (HCC) still remains unclear. A tissue microarray containing 38 HCCs and adjacent non-tumorous liver tissue samples was constructed. The microvessel density (MVD) of CD31, CD105, vWF and the expression of PCNA, VEGF were investigated in a HCC tissue microarray by immunohistochemistry. There was a significant difference between the score of MVD-CD31 in HCC (48.5 ± 29.7) and non-tumorous liver tissue (24.2 ± 22.3, P|0.01). The mean score of MVD-CD31 was higher in HCCs with high PCNA expression (68.4 ± 37.0) than in HCCs with low PCNA expression (37.9 ± 30.9, P = 0.012). MVD-CD105 and VEGF expression were significantly higher in HCC with intrahepatic metastasis (P | 0.01). Multivariate
TY - JOUR. T1 - Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria. T2 - a retrospective, exploratory analysis. AU - Mazzaferro, Vincenzo. AU - Llovet, Josep M.. AU - Miceli, Rosalba. AU - Bhoori, Sherrie. AU - Schiavo, Marcello. AU - Mariani, Luigi. AU - Camerini, Tiziana. AU - Roayaie, Sasan. AU - Schwartz, Myron E.. AU - Grazi, Gian Luca. AU - Adam, René. AU - Neuhaus, Peter. AU - Salizzoni, Mauro. AU - Bruix, Jordi. AU - Forner, Alejandro. AU - De Carlis, Luciano. AU - Cillo, Umberto. AU - Burroughs, Andrew K.. AU - Troisi, Roberto. AU - Rossi, Massimo. AU - Gerunda, Giorgio E.. AU - Lerut, Jan. AU - Belghiti, Jacques. AU - Boin, Ilka. AU - Gugenheim, Jean. AU - Rochling, Fedja A. AU - Van Hoek, Bart. AU - Majno, Pietro. PY - 2009/1/1. Y1 - 2009/1/1. N2 - Background: Patients undergoing liver transplantation for hepatocellular carcinoma within the Milan criteria (single tumour ≤5 cm in size or ≤3 tumours each ≤3 cm in ...
Abdel-Rahman O, Elsayed Z. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013431. DOI: 10.1002/14651858. ...
TY - JOUR. T1 - Delphinidin induces necrosis in hepatocellular carcinoma cells in the presence of 3-methyladenine, an autophagy inhibitor. AU - Feng, Rentian. AU - Wang, Shiow Y.. AU - Shi, Ying Hong. AU - Fan, Jia. AU - Yin, Xiao-Ming. PY - 2010/4/14. Y1 - 2010/4/14. N2 - The present study was performed to determine whether anthocyanins could trigger different modes of cell death in different cancers. It was found that whereas cyanidin-3-rutinoside and delphinidin could induce apoptosis in leukemia cells, they caused growth retardation in hepatocellular carcinoma cells (HCC), which was accompanied with a significant cellular vacuolization. The latter was likely caused by macroautophagy and was completely suppressed by 3-methyladenine, an inhibitor of class III phosphoinositide 3-kinase that is important for autophagy activation, and by bafilomycin A1, which blocks lysosomal degradation. Delphinidin induced significant lipidation of LC3, an indication of macroautophagy, which was also suppressed ...
Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced HCC. Octreotide is used in t
The molecular mechanism of tumor angiogenesis has been well described (25,26). Vascular endothelial growth factor (VEGF) and the angiopoietin (Ang) family are vascular endothelium-specific growth factors (25). In HCCs, the correlation between such growth factors and MVD has been revealed in several studies (27-29). In addition, another study demonstrated that the stromal cells in solid tumors play an important role in tumor progression (30).. TAMs are particularly important components of the tumor microenvironment (12,13). Macrophages are released from bone marrow, then circulate in the blood stream and migrate into tissues such as Kupffer cells in the liver. These macrophages are capable of lysing tumor cells, presenting antigens to T cells, and expressing immunostimulatory cytokines (12). In contrast, TAMs which are exposed to tumor-derived molecules such as interleukin (IL)-4 and IL-10 and are alternatively activated have poor antigen-presenting capability, and they produce factors that ...
Backgrounds: Recently Hong Kong Liver Cancer (HKLC) staging system has been proposed for staging of hepatocellular carcinoma (HCC), and has been shown to provide better prognostic ability than the Barcelona Clinic Liver Cancer (BCLC) system. However, the HKLC system lacks external validation, and its applicability remains uncertain. The present study was aimed to evaluate the prognostic performance of HKLC in HCC patients treated with curative intent. Methods: Medical records of HCC patients treated with either resection or radiofrequency ablation (RFA) from 2011 to 2016 were retrospectively reviewed. The overall survival and the prognostic ability of the HKLC and BCLC system were evaluated. Results: 79 HCC patients were included, of which 64.56% had Child A cirrhosis. Chronic viral hepatitis B infection was the leading cause of HCC, followed by chronic viral hepatitis C infection, alcohol and alcohol with HBV or HCV infection. According to the BCLC system, 82.28% were in stage 0-A, and according to
Objective. To determine the prevalence of testing for hepatitis B virus HBV infection in the clinical management of primary liver cancer hepatocellular carcinoma. Methods. The authors reviewed the records of 78 patients treated for hepatocellular carcinoma in hospitals in the Puget Sound area in 1988 and early 1989 and reviewed all 1990 U.S....
Hepatitis B viral infection-induced hepatocellular carcinoma is one of the major problems in the developing countries. One of the HBV proteins, HBx, modulates the host cell machinery via several mechanisms. In this study we hypothesized that HBV enhances cell proliferation via HBx-induced microRNA-21 in hepatocellular carcinoma. HBx gene was over-expressed, and miRNA-21 expression and cell proliferation were measured in Huh 7 and Hep G2 cells. miRNA-21 was over-expressed in these cells, cell proliferation and the target proteins were analyzed. To confirm the role of miRNA-21 in HBx-induced proliferation, Hep G 2.2.1.5 cells (a cell line that expresses HBV stably) were used for miRNA-21 inhibition studies. HBx over-expression enhanced proliferation (3.7- and 4.5-fold increase; n = 3; p|0.01) and miRNA-21 expression (24- and 36-fold increase, normalized with 5S rRNA; p|0.001) in Huh 7 and Hep G2 cells respectively. HBx also resulted in the inhibition of miRNA-21 target proteins, PDCD4 and PTEN. miRNA-21
TY - JOUR. T1 - Loco-regional interventional treatment of hepatocellular carcinoma. T2 - Techniques, outcomes, and future prospects. AU - Lencioni, Riccardo. AU - Crocetti, Laura. AU - De Simone, Paolo. AU - Filipponi, Franco. PY - 2010. Y1 - 2010. N2 - Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of ...
MicroRNAs (miRNAs) are a class of small non-coding RNAs that, in general, negatively regulate gene expression. They have been identified in various tumor types, showing that different sets of miRNAs are usually deregulated in different cancers. Some miRNA genes harboring CpG islands undergo methylation-mediated silencing, a characteristic of many tumor suppressor genes. To identify such miRNAs in hepatocellular carcinoma (HCC), we first examined the methylation status of 43 loci containing CpG islands around 39 mature miRNA genes in a panel of HCC cell lines and non-cancerous liver tissues as controls. Among 11 miRNA genes frequently methylated in HCC cell lines but not in non-cancerous liver tissues, three miRNA genes, i.e. miR-124, miR-203 and miR-375, were selected as silenced miRNAs through CpG-island methylation by comparing methylation and expression status and evaluating restored expression after treatment with 5-aza-2′-deoxycytidine. In primary tumors of HCC with paired non-tumorous ...
Abdominal ultrasonograms are often obtained for the initial evaluation of patients with abdominal pain; therefore, ultrasonography may be the first imaging study available in patients with fibrolamell... more
DISCUSSION. Management of hepatocellular carcinoma requires a multidisciplinary approach involving the hepatologist, interventional radiologist and liver surgeon. The major prognostic factors in HCC patients are related to tumor characteristics namely number and size of tumor nodules, presence of vascular invasion and extra-hepatic invasion, host factors such as degree of liver function defined by Child-Pughs class and general health status defined by Eastern Co-operative Oncology Group (ECOG) status.19 BCLC staging classification is based on these factors to stratify patients in 5 stages (0, A, B, C and D) and to allocate therapies according to the stage.4 According to European Association of Study of Liver recommendations,18 TACE is first line-therapy in intermediate HCC BCLC stage B and sorafenib in advanced HCC BCLC stage C.. The rationale for TACE is intra-arterial infusion of a cytotoxic agent followed by embolization of the tumorfeeding blood vessels with an aim to achieve strong ...
TY - JOUR. T1 - Hepatocellular carcinoma presenting with bone metastasis. T2 - Clinical characteristics and prognostic factors. AU - Kim, Seung Up. AU - Kim, Do Young. AU - Park, Jun Yong. AU - Ahn, Sang Hoon. AU - Nah, Hyung Joong. AU - Chon, Chae Yoon. AU - Han, Kwang Hyub. PY - 2008/12/1. Y1 - 2008/12/1. N2 - Purpose: The survival of patients with hepatocellular carcinoma (HCC) has been prolonged with improvements in various diagnostic tools and treatment modalities. Consequently, bone metastases from HCC are diagnosed more frequently. We investigated the clinical features, prognosis, treatment outcomes, and prognostic factors of HCC presenting with bone metastasis. Methods: Between June 2000 and April 2007, we recruited 37 consecutive HCC patients presenting with bone metastasis. These patients were divided into an untreated control group (n = 16) and a treated group (n = 21). Results: The mean age of the patients was 61.1 years (male:female, 31:6). The most common cause of HCC was hepatitis ...
Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib
Altogether 19% of patients responded to the antibody targeting programmed cell death protein 1 (PD-1), with a median duration of response of 17 months in the dose-escalation cohort and not reached in the expansion cohort. At 9 months, more than 70% of patients were alive, reported Ignacio Melero, MD, of Clinca Universidad de Navarra in Pamplona, Spain, who presented the findings from the global phase II trial at the 2017 Gastrointestinal Cancers Symposium.. "Nivolumab monotherapy provided early, stable, and durable responses. Efficacy was observed irrespective of hepatitis C or B viral infection status, and responses were durable irrespective of PD-L1 [programmed cell death ligand 1] expression on tumor cells," said Dr. Melero.. CheckMate 040 Findings. CheckMate 040 enrolled 262 patients with advanced hepatocellular carcinoma, treating them with nivolumab at 0.1 to 10 mg/kg in the dose-escalation phase (n = 48) and at 3 mg/kg in the dose-expansion phase (n = 214). Previous treatment with ...
Hepatitis B virus x protein induces epithelial-mesenchymal transition of hepatocellular carcinoma cells by regulating long non-coding RNA. https://t.co/ewvzsLK8Xn https://t.co/18bd2tE7UL. ...
To extend the search for hepatocellular carcinoma (HCC) associated antigens with immunogenicity for clinical applications. we constructed a cDNA expression library using resected human HCC tissue sample and screened it by serological analysis of recombinant cDNA expression library (SEREX) with autologous and allogeneic sera. A total of 24 distinct antigens were isolated and kinectin was the antigen most frequently identified. We found that kinectin was alternatively spliced at four sites and obtained all eight theoretical forms of variant, six by SEREX and two by RT-PCR, from the different splicing combinations of the last three sites. In addition, the splicing patterns of four sites were analyzed. Variant containing D2 was overexpressed in cancerous tissues and this alteration may be tumor associated. The four splicing sites. the variants generated by alternative splicing, and the humoral immune response in HCC patients, may help to analyze the role of kinectin in human HCC cell biology. ...
In the race for better treatments and possible cures, rare diseases are often left behind. In a collaboration of researchers at The Rockefeller University, Memorial Sloan Kettering Cancer Center and the New York Genome Center (NYGC), an unusual mutation has been found that is strongly linked to one such disease: a rare liver cancer that affects teens and young adults. The results, published this week in Science, suggest that the mutation plays a key role in the development of the disease, called fibrolamellar hepatocellular carcinoma, and may also underlie more common cancers as well. (Source: Health News from Medical News Today ...
Ki67 pCEA Vimentin. What is your diagnosis?. Diagnosis: Hepatocellular carcinoma, fibrolamellar variant. Discussion:. Fibrolamellar hepatocellular carcinoma is uncommon, and usually affects young adults aged 20-40 years (eMedicine). It accounts for fewer than 10% of all cases of HCC, but 35% of all cases in patients younger than 50 years. Fibrolamellar carcinoma is typically not associated with underlying liver disease, jaundice or elevated serum levels of alpha-fetoprotein. The tumors are typically large at diagnosis (mean 10-20 cm), with regional lymph node metastases in 50-70%. Microscopically, fibrolamellar carcinomas have nests, sheets or cords of malignant cells, which are separated by lamellar bands of dense, hypocellular collagen connective tissue. The fibrotic connective tissue coalesces into the central scar. The malignant cells are usually large, well-differentiated polygonal cells containing granular cytoplasm, large nuclei, and prominent nucleoli (Adv Anat Pathol 2007;14:217). ...
Retraction Note: Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model
In human cancers, giant cadherin FAT1 may function both, as an oncogene and a tumor suppressor. Here, we investigated the expression and function of FAT1 in hepatocellular carcinoma (HCC). FAT1 expression was increased in human HCC cell lines and tissues compared with primary human hepatocytes and non-tumorous liver tissue as assessed by quantitative PCR and western blot analysis. Combined immunohistochemical and tissue microarray analysis showed a significant correlation of FAT1 expression with tumor stage and proliferation. Suppression of FAT1 expression by short hairpin RNA impaired proliferation and migration as well as apoptosis resistance of HCC cells in vitro. In nude mice, tumors formed by FAT1-suppressed HCC cells showed a delayed onset and more apoptosis compared with tumors of control cells. Both hepatocyte growth factor and hypoxia-mediated hypoxia-inducible factor 1 alpha activation were identified as strong inducers of FAT1 in HCC. Moreover, demethylating agents induced FAT1 ...
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. Recurrence and metastasis after curative resection remain critical obstacles in HCC treatment. CD146 predicted poor prognosis of a variety of cancers including melanoma, breast tumors, prostate cancer, and gastric cancer. However, the role of CD146 in HCC has not yet been systematically explored. To investigate the role of CD146 in HCC, we evaluated its expression in HCC tissues and HCC cell lines using real-time PCR and western blotting (WB). Second, we established HCC cell lines that stably overexpressed and interfered CD146 and explored the function of CD146 in HCC in vitro and in vivo. Third, we conducted microarray analysis to investigate the potential mechanism by identifying differentially expressed genes. Last, follow ups were conducted to help uncover the connection of CD146 expression and the prognosis of HCC patients. We found that CD146 was overexpressed in HCC tissues and that high CD146
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. Recurrence and metastasis after curative resection remain critical obstacles in HCC treatment. CD146 predicted poor prognosis of a variety of cancers including melanoma, breast tumors, prostate cancer, and gastric cancer. However, the role of CD146 in HCC has not yet been systematically explored. To investigate the role of CD146 in HCC, we evaluated its expression in HCC tissues and HCC cell lines using real-time PCR and western blotting (WB). Second, we established HCC cell lines that stably overexpressed and interfered CD146 and explored the function of CD146 in HCC in vitro and in vivo. Third, we conducted microarray analysis to investigate the potential mechanism by identifying differentially expressed genes. Last, follow ups were conducted to help uncover the connection of CD146 expression and the prognosis of HCC patients. We found that CD146 was overexpressed in HCC tissues and that high CD146
TY - JOUR. T1 - Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma. AU - Yu, Le. AU - Huang, Xiaobin. AU - Zhang, Wenfa. AU - Zhao, Huakan. AU - Wu, Gang. AU - Lv, Fenglin. AU - Shi, Lei. AU - Teng, Yong. PY - 2016/5/1. Y1 - 2016/5/1. N2 - Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality globally. Therefore, it is quite essential to identify novel HCC-related molecules for the discovery of new prognostic markers and therapeutic targets. As an oncogene, DEK plays an important role in cell processes and participates in a variety of cellular metabolic functions, and its altered expression is associated with several human malignancies. However, the functional significance of DEK and the involved complex biological events in HCC development and progression are poorly understood. Here, combing the results from clinical specimens and cultured cell lines, we uncover a critical oncogenic role of DEK, which is highly ...
MicroRNAs (miRNAs) are a group of small RNAs with a fundamental role in the regulation of gene expression. These RNAs have been shown to participate in various cellular and physiological processes, including cellular development, apoptosis, proliferation, and differentiation. Aberrant expression of several miRNAs was found to be involved in a large variety of neoplasms, including hepatocellular carcinoma (HCC). Previous studies have shown the existence of a large amount of stable miRNAs in human serum/plasma, which laid the foundation for studying the role of serum/plasma miRNAs in the diagnosis and prognosis of HCC. Here, we review the recent progress in research on serum miRNAs as biomarkers for HCC in Chinese patients.
Cell lines and tissue culture. Human hepatocellular carcinoma cell lines Hep3B, PLC/PRF/5, and HepG2; human cervix epithelial adenocarcinoma cell line HeLa; human lung carcinoma cell line A549; human tumor cell line SK-Hep-1; human 293 cell line; rat hepatocellular carcinoma cell lines McA-RH7777 and MHC1; and normal rat hepatocyte clone 9 were obtained from American Type Culture Collection (Manassas, VA). 293 cells expressing Cre recombinase (293Cre4) were obtained from Merck Research Laboratories (West Point, PA).. Animals. Seven-week-old female BALB/c nude mice and BALB/c mice were purchased from Charles Rivers Laboratories (Barcelona, Spain). Four- to 6-week-old male Buffalo rats were obtained from Harlan (Barcelona, Spain). The animals were kept under standard pathogen-free conditions and were handled according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals by the National Academy of Sciences. All experiments were done in accordance with the local animal ...
1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255 2. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, Kimoto T. et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg. 1993;217:375-384 3. Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC. et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012;56:595-601 4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576 5. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022 6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-1127 7. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-799 8. Liu M, Jiang L, Guan XY. The genetic and ...
PURPOSE To determine MR-imaging features for the differentiation between hepatocellular carcinoma (HCC) and benign hepatocellular tumors in the non-cirrhotic liver. MATERIAL AND METHODS 107 consecutive patients without liver cirrhosis (46 male; 45±14 years) who underwent liver resection due to suspicion of HCC were included in this multi-center study. The following imaging features were assessed: lesion diameter and demarcation, satellite-lesions, central-scar, capsule, fat-content, hemorrhage, vein-infiltration and signal-intensity (SI) on native T1-, T2- and dynamic-enhanced T1-weighted images (center versus periphery). In addition, contrast-media (CM) uptake in the liver specific phase was analyzed in a sub-group of 42 patients. RESULTS Significant differences between HCC (n=55) and benign lesions (n=52) were shown for native T1-, T2- and dynamic-enhanced T1-SI, fat-content, and satellite-lesions (all, P,.05). Independent predictors for HCC were T1-hypointensity (odds-ratio, 4.81), ...
Clinical trial for HEPATIC NEOPLASM | HEPATOCELLULAR CARCINOMA , A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Clinical trial for HEPATIC NEOPLASM | HEPATOCELLULAR CARCINOMA , A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Hepatocellular Carcinoma Or Liver Cancer: Causes, Clinal Features, Diagnosis and Management • Hepatocellular carcinoma (HCC) is a primary malignancy of the
We report here two cases of hepatocellular carcinoma (HCC) 90 and 70 months, respectively, after successful treatment with interferon (IFN) and ribavirin for hepatitis C virus (HCV)-related cirrhosis. A 50-year-old Caucasian man and a 66-year-old Caucasian woman with HCV-related cirrhosis were treated with IFN and ribavirin and in both cases a sustained virological response (SVR) was obtained with persistent normalization of serum aminotransferases and continuous disappearance of serum HCV-RNA. Both patients were subsequently followed up within an HCC surveillance programme based on biochemical and ultrasound (US) evaluation every 6 months and the appearance of HCC was detected 90 and 70 months, respectively, after discontinuation of therapy. We introduce these two cases to call attention to the importance of not underestimating the risk of HCC development even many years after complete HCV eradication, especially in the presence of established cirrhosis and concomitance of other risk factors ...
BACKGROUND: Sorafenib (Sor) is the only approved systemic therapy for advanced HCC yet the safety and efficacy for its use in patients (pts) who developed recurrence after liver transplantation (LT) has not been established. There is an unmet need for treatment option in this group of pts. METHODS: This is a retrospective analysis of pts treated with Sor for recurrent HCC post-LT in Queen Mary Hospital, Hong Kong. RESULTS: During year Jan 2008 to Feb 2014, 25 post-LT pts with HCC recurrence were treated with Sor. Tacrolimus and sirolimus were the immunosuppressant of choice during the same treatment period in 76% (19/25) and 40% (10/25) pts respectively. All pts had Child-Pugh A liver function and ECOG performance status 0-1. Majority of pts were chronic hepatitis B carriers (88%) and male (88%). Median time to recurrence was 13.2 months (range 3.4-71.1). Intrahepatic recurrence and extrahepatic recurrence were found in 52% and 80% of pts respectively. Up to 68% of pts received the standard dose ...
Press Release 15 August 2017 Immunicum AB (publ) Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the last patient last visit in the ongoing Phase I/II study of ilixadencel in hepatocellular carcinoma (HCC). The open label study enrolled eighteen patients and was conducted at the Sahlgrenska University Hospital at Gothenburg University. Topline results from the study following data analysis are anticipated before the end of the year. Ilixadencel, formerly known as INTUVAX, is a cancer immune primer developed for the treatment of solid tumors and is currently also being investigated in an ongoing Phase II trial in renal cell carcinoma (MERECA) as well as a Phase I/II study in gastrointestinal stromal tumors. Todays announcement continues the significant progress we have made
Mitotically‑associated long non‑coding RNA (MANCR) is involved in malignant breast cancer. The present study analyzed the role of MANCR in hepatocellular carcinoma (HCC). MANCR was found to be upregulated in HCC and high expression level of MANCR in cancer tissues predicted poor survival of HCC patients. MicroRNA (miR)‑122a was downregulated HCC and was inversely correlated with MANCR only in cancer tissues. MANCR overexpression resulted in downregulation of miR‑122a, while miR‑122a overexpression showed no obvious effects on MANCR expression. MANCR overexpression showed no significant effects on HCC cell proliferation but led to promoted cell migration and invasion. miR‑122a overexpression led to inhibited migration and invasion of HCC cells and attenuated the effects of MANCR overexpression. Therefore, lncRNA MANCR may promote cancer cell proliferation in HCC by downregulating miR‑122a ...
Hep G2 cell line slides (human: liver; hepatocellular carcinoma), HepG2 (human liver; hepatocellular carcinoma) cell line slides, GTX25530, Applications: ICC/IF; Immunocytochemistry/ Immunofluorescence (ICC/IF); CrossReactivity:
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90 2. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753-770 3. Li S, Sun R, Chen Y, Wei H, Tian Z. TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression. Cancer Res. 2015;75:986-995 4. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-124 5. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, Hoffman RM, Tateishi R, Koike K, Karin M. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155:384-396 6. Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, Pan JF, Yan J, ...
People with diabetes have a two- to threefold higher risk for hepatocellular carcinoma compared with those without diabetes," said V. Wendy Setiawan, Ph.D., assistant professor in the Department of Preventive Medicine at Keck School of Medicine of the University of Southern California. "We also found that the interethnic differences in the prevalence of diabetes were consistent with the pattern of hepatocellular carcinoma incidence observed across ethnicities: Ethnic groups with a high prevalence of diabetes also have high hepatocellular carcinoma rates, and those with a lower prevalence of diabetes have lower hepatocellular carcinoma rates.". The number of new cases of hepatocellular carcinoma in the United States tripled in the past three decades, with Latinos and African-Americans experiencing the largest increase in incidence. Prior research has suggested that diabetes may be a risk factor for hepatocellular carcinoma, and its increasing incidence may be contributing to the rising rate of ...
Hepatocellular carcinoma (HCC) treatment is challenging because the mechanisms underlying tumor progression are still largely unknown. Transforming growth factor (TGF)-beta 1 is considered a crucial molecule in HCC tumorigenesis because increased levels of patients serum and urine are associated with disease progression. The aim of the present study was to investigate the inhibition of TGF-beta signaling and its impact on HCC progression. Human HCC cell lines were treated with a TGF-beta receptor kinase inhibitor (LY2109761) whose selectivity was determined in a kinase assay. Exogenous TGF-beta 1 phosphorylates the TGF-beta receptor, consequently activating Smad-2, whereas the drug selectively blocks this effect and dephosphorylates autocrine p-Smad-2 at concentrations ranging from 0.001 to 0.1 mu M. A cytotoxic effect documented by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), trypan blue, and propidium iodide staining assays was observed at 10 mu M, whereas the drug ...
Cost-effectiveness of screening for hepatocellular carcinoma: putting the cart before the horse Alain BraillonGRES, Public Health, Amiens, FranceRuggeri has recently reviewed the cost-effectiveness of screening for hepatocellular carcinoma (HCC).1 However, evidence for effectiveness is still lacking, with only two randomized trials available, both from China, one of which is negative and the other positive but with several major flaws.2 Only observational studies are available from developed countries, and conclude that screening improves survival, despite raw data showing that screened patients die younger than nonscreened patients, (length time and lead time biases).3 The National Cancer Institute recommends that “based on fair evidence, screening would not result in a decrease in mortality from HCC … based on fair evidence, screening would result in rare but serious side effects”.4View original paper by Ruggeri.
Hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is a primary malignancy of the hepatocyte , derived from well-differentiated hepatocytes , generally leading to death within 6-20 months. Slideshow 2240806 by tryna
Its only fair to share… FGF 401 NVP-FGF-401 CAS 1708971-55-4 MF C25 H30 N8 O4, MW 506.56 1,8-Naphthyridine-1(2H)-carboxamide, N-[5-cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]- N-[5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-1,8-naphthyridine-1(2H)-carboxamide /V-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1 -yl)methyl)-3,4-dihydro-1 ,8-naphthyridine-1 (2H)-carboxamide Phase I/II Hepatocellular carcinoma; Solid tumours Originator Novartis Developer Novartis Oncology Class Antineoplastics Mechanism of Action Type 4 fibroblast growth factor receptor antagonists 26 Jan 2016 Phase-I/II clinical trials in Solid tumours and Hepatocellular carcinoma in USA, Hong …. Read more ...
Note the mosaic enhancement of tumoural liver infavor of hepatocellular carcinoma. Related article hepatocellular carcinoma
Recent research by Fior Markets on Global Hepatocellular Carcinoma Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 gives a significant examination of Hepatocellular Carcinoma Drugs market: industry analysis, size, share, growth, trends, outlook and forecasts 2019-2024 present in the industry space. The market intelligence was prepared to focus on the present trends, historical data evaluation, and financial research of the industry based on the complete market dynamics. By offering them a clear picture of this market, the report causes the user to reinforce the exhaustive capacity to design their key moves to extend their organizations. Deeply examined company profiles are presented on the basis of global market size, share, and revenue projection. The report calculates the current market performance by taking several key factors into accounts such as key drivers, opportunities, trends, and challenges.. The market size is given with market revenue, covering ...
Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3-targeted magnetic resonance imaging, positron emission tomography, and near-infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have ...
See Article on [Related article:] 239. Early detection of hepatocellular carcinoma (HCC) is very important because the 5-year survival rate of early stage HCC (about 40% to 70%) is better than that of advanced stage HCC (less than 5%) [1]. In some countries, high-risk patients undergo a hepatocarcinoma surveillance program using ultrasound and serum alpha-fetoprotein (AFP) levels.. However, there are several drawbacks of surveillance program using ultrasonography. For high chance of receiving curative treatment, the stage of HCC should be low, such as very early (BCLC 0) or early (BCLC A) stage. However, detection of small lesions by ultrasound is not easy. According to a meta-analysis [2], the sensitivity of ultrasonography was 65% to 80%. Although accompanying with measurement of serum AFP, the sensitivity to detect early HCC was not increased [3]. Therefore, it seems not to be enough to perform ultrasonography as the only imaging method for surveillance of HCC. According to a retrospective ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Abdominal Pain & Fibrolamellar Hepatocellular Carcinoma & Hepatorenal Syndrome Symptom Checker: Possible causes include Hepatocellular Carcinoma. Check the full list of possible causes and conditions now! Talk to our Chatbot to narrow down your search.
Although transarterial chemoembolization (TACE) has been used extensively for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), no consensus has been reached and an evidence base for practice is lacking. This meta-analysis evaluated the efficacy and safety of TACE for treatment of HCC with PVTT. Ovid Medline, EMBASE, Web of Knowledge, and Cochrane library databases were searched up to August 2012 for controlled trials assessing TACE in patients with PVTT. Data concerning the study design, characteristics of trials, and outcomes were extracted. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using random effects models. Eight controlled trials involving 1601 HCC patients were included. TACE significantly improved the 6-month (HR, 0.41; 95% CI: 0.32-0.53; z, 6.28; p = 0.000) and 1-year (HR, 0.44; 95% CI: 0.34-0.57; z, 6.22; p = 0.000) overall survival of patients with PVTT compared with conservative treatment. Subgroup analyses showed that TACE was
TY - JOUR. T1 - Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas. T2 - Frequency and risk factors. AU - Choi, Dongil. AU - Lim, Hyo K.. AU - Kim, Min Ju. AU - Kim, Suk Jung. AU - Kim, Seung Hoon. AU - Lee, Won Jae. AU - Lim, Jae Hoon. AU - Paik, Seung Woon. AU - Yoo, Byung Chul. AU - Choi, Moon Seok. AU - Kim, Seonwoo. PY - 2005/1/1. Y1 - 2005/1/1. N2 - OBJECTIVE. The purpose of this study was to clarify the frequency and risk factors of liver abscess formation after percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. MATERIALS AND METHODS. Over a 4-year period, 603 patients with 831 hepatocellular carcinomas measuring 5 cm or less in maximum diameter who underwent a total of 751 percutaneous radiofrequency ablation procedures were enrolled in this study. We retrospectively reviewed the medical records and analyzed the overall frequency of liver abscess, risk factors for abscess, and clinical features of the patients. The ...
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage ...
Objective The efficacy of combination transcatheter arterial chemoembolization(TACE) with subsequent percutaneous microwave coagulation therapy (PMCT)was assessed.Methods Eighteen patients with 28 tumors under TACE followed within 1~2 days by ultrasound guided PMCT,which were diagnosed by liver biopsy.Results Ninteen tumors measuring 5 cm in greatest dimension showed complete necrosis,5 of 9 tumors measuring ≥5 cm in greatest dimension showed complete necrosis.Conclusions Combination therapy with TACE and PMCT for liver tumor is effective.
Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumors blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways. The radiotherapeutic analogue (combining radiotherapy with embolization) is called radioembolization or selective internal radiation therapy (SIRT). TACE derives its beneficial effect by two primary mechanisms. Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumors blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of a higher dose to the tissue while simultaneously reducing systemic exposure, ...
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in most Asian countries due to the high prevalence of hepatitis B viral infection.1 Surgical resection and liver transplantation are regarded as the main curative treatments for HCC. Many patients, however, are not eligible for resection due to locally advanced tumour, underlying liver cirrhosis with suboptimal liver reserve or metastatic disease on presentation.1. Puppala et al2 concisely summarise the modern image-guided therapy options for patients with advanced HCC, such as radiofrequency ablation (RFA), microwave ablation, percutaneous ethanol ablation (PEI), cryoablation, transarterial chemoembolisation (TACE) and yttrium-90 radioembolisation. However, most of these treatments are palliative in nature and the overall survival of HCC patients with locally advanced disease remains poor. The outcomes of these image-guided therapies depend on accurate tumour staging, the position of the tumour in the liver, ...
Status: Recruiting. Condition Summary: Adrenal Cortex Carcinoma; Adult Alveolar Soft Part Sarcoma; Adult Clear Cell Sarcoma of Soft Parts; Adult Hepatocellular Carcinoma; Adult Rhabdomyosarcoma; Adult Soft Tissue Sarcoma; Childhood Alveolar Soft Part Sarcoma; Childhood Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Parts; Childhood Hepatocellular Carcinoma; Childhood Rhabdomyosarcoma; Childhood Soft Tissue Sarcoma; Childhood Solid Neoplasm; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Recurrent Adrenal Cortex Carcinoma; Recurrent Adult Hepatocellular Carcinoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Hepatocellular Carcinoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Malignant Solid Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Renal Cell Carcinoma; Thyroid Gland Medullary ...
TY - JOUR. T1 - Heterotopic liver transplantation for fulminant Wilsons disease. AU - Stampfl, David A.. AU - Muñoz, Santiago J.. AU - Moritz, Michael J.. AU - Rubin, Raphael. AU - Armenti, Vincent T.. AU - Jarrell, Bruce E.. AU - Maddrey, Willis C.. PY - 1990. Y1 - 1990. N2 - Wilsons disease may present with severe acute hepatocellular failure. The only effective treatment for fulminant Wilsons disease is liver transplantation, which may lead to reversal of the underlying disease. Some patients with cirrhosis who are too ill to undergo orthotopic liver transplantation have been treated with heterotopic liver transplantation. However, use of heterotopic liver transplantation for fulminant hepatocellular failure has not been successful. This case study involves a patient in whom a heterotopic liver transplant was successfully used for treatment of Wilsons disease presenting with fulminant hepatocellular failure.. AB - Wilsons disease may present with severe acute hepatocellular failure. The ...

Metastatic Hepatocellular Carcinoma (HCC) Market - Revenue, Demands, Industry Analysis, Trends, Growth, and Forecast, 2016 -...Metastatic Hepatocellular Carcinoma (HCC) Market - Revenue, Demands, Industry Analysis, Trends, Growth, and Forecast, 2016 -...

Metastatic Hepatocellular Carcinoma (HCC) market report covers research informatics related to Metastatic Hepatocellular ... Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Phase, 2016. *Metastatic Hepatocellular ... Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Key Sponsors, 2016. *Metastatic Hepatocellular ... Metastatic Hepatocellular Carcinoma (HCC) Market Scope: *The report provides a snapshot of the global clinical trials landscape ...
more infohttp://beforeitsnews.com/healthcare/2016/11/metastatic-hepatocellular-carcinoma-hcc-market-revenue-demands-industry-analysis-trends-growth-and-forecast-2016-2020-2488204.html

Fibrolamellar hepatocellular carcinoma - wikidocFibrolamellar hepatocellular carcinoma - wikidoc

Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of primary liver cancer. Fibrolamellar hepatocellular carcinoma ... Differentiating Fibrolamellar Hepatocellular Carcinoma from Other Diseases. *Fibrolamellar hepatocellular carcinoma must be ... Fibrolamellar hepatocellular carcinoma is usually asymptomatic.. *Symptoms of fibrolamellar hepatocellular carcinoma may ... Review articles on Fibrolamellar hepatocellular carcinoma Articles on Fibrolamellar hepatocellular carcinoma in N Eng J Med, ...
more infohttp://es.wikidoc.org/index.php/Fibrolamellar_hepatocellular_carcinoma

Hepatocellular Carcinoma | SpringerLinkHepatocellular Carcinoma | SpringerLink

... characterization and novel gene-isolation techniques have vigorously expanded our understanding of hepatocellular carcinoma ( ... In Hepatocellular Carcinoma: Methods and Protocols, Nagy Habib and a team of basic and clinical researchers describe the wide ... Hepatocellular Carcinoma: Methods and Protocols offers experimental and clinical investigators a rich source of both basic ... Measurement of Protein Expression of p53, p21WAF1, and Rb in Patients with Surgically Treated Hepatocellular Carcinoma by Using ...
more infohttps://link.springer.com/book/10.1385/1592590799

Hepatocellular carcinomaHepatocellular carcinoma

Cancer that originates in the cells of the liver; this type of cancer may develop in those who have certain forms of cirrhosis or who have had a hepatitis B or hepatitis C infection; may develop years after initial infection. ...
more infohttps://labtestsonline.org/glossary/hepatocellular

Hepatocellular carcinoma.  - PubMed - NCBIHepatocellular carcinoma. - PubMed - NCBI

Hepatocellular carcinoma.. Forner A1, Llovet JM, Bruix J.. Author information. 1. Barcelona Clinic Liver Cancer group, Liver ... Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Patients ... Findings of randomised trials of sorafenib have shown survival benefits for individuals with advanced hepatocellular carcinoma ... Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/22353262?access_num=22353262&link_type=MED&dopt=Abstract

Hepatocellular carcinoma.  - PubMed - NCBIHepatocellular carcinoma. - PubMed - NCBI

This year the number of papers published regarding hepatocellular carcinoma (HCC) continued to increase compared with last year ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/15703649?dopt=Abstract

Hepatocellular Carcinoma --- United States, 2001--2006Hepatocellular Carcinoma --- United States, 2001--2006

... Liver cancer, primarily hepatocellular carcinoma (HCC), is the third ... Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009;101 ... Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths in the United States and worldwide; infection with hepatitis ... Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27 ...
more infohttps://www.cdc.gov/mmwr/preview/mmwrhtml/mm5917a3.htm

Hepatocellular Carcinoma News, ResearchHepatocellular Carcinoma News, Research

Hepatocellular Carcinoma News and Research. RSS Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of ... Hepatocellular carcinoma is the most common form of liver cancer, and the third biggest cause of death from cancer worldwide. ... Patients with hepatocellular carcinoma (HCC) waiting for a liver transplant in the USA are now significantly less likely to ... New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma Chronic hepatitis B virus (HBV) can progress ...
more infohttps://www.news-medical.net/?tag=/Hepatocellular+Carcinoma

Liver Cancer | Hepatocellular Carcinoma | MedlinePlusLiver Cancer | Hepatocellular Carcinoma | MedlinePlus

The most common form of liver cancer in adults is hepatocellular carcinoma. Learn about diagnosis, treatment and taking part in ... ClinicalTrials.gov: Carcinoma, Hepatocellular (National Institutes of Health) * ClinicalTrials.gov: Hepatoblastoma (National ... Liver (Hepatocellular) Cancer Screening (National Cancer Institute) Also in Spanish * Liver Biopsy (National Institute of ... Risks of Liver (Hepatocellular) Cancer Screening (National Cancer Institute) Also in Spanish ...
more infohttps://medlineplus.gov/livercancer.html

Liver Transplantation for Hepatocellular Carcinoma | SpringerLinkLiver Transplantation for Hepatocellular Carcinoma | SpringerLink

... for hepatocellular carcinoma (HCC) in the United States in 1963. In the worlds first 7 LTs, 3 of them were performed for HCC ... Expanded criteria for hepatocellular carcinoma and liver transplantation. Transplant Proc, 2007, 39: 1171-1174.PubMedCrossRef ... Management of hepatocellular carcinoma in the waiting list before liver transplantation. J Hepatol, 2005, 42: S134-S143.PubMed ... Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008, 85: 1726-1732.PubMedCrossRef ...
more infohttps://link.springer.com/chapter/10.1007/978-3-642-28702-2_14

Metastasis in Patients With Hepatocellular CarcinomaMetastasis in Patients With Hepatocellular Carcinoma

... and prognostic impact of metastasis in hepatocellular carcinoma, proposing a modified BCLC system based on metastasis. ... Extrahepatic metastasis of hepatocellular carcinoma (HCC) is not uncommon. However, its prognostic effect is not fully studied. ... Hepatocellular carcinoma patients with metastasis at the time of diagnosis have shorter overall survival compared to patients ... Re-allocating 181 hepatocellular carcinoma (HCC) patients with a combination of vascular invasion and metastasis from Barcelona ...
more infohttps://www.medscape.com/viewarticle/902850_3

External Beam Radiotherapy for Hepatocellular carcinomaExternal Beam Radiotherapy for Hepatocellular carcinoma

Latest advances in external beam radiotherapy for hepatocellulalar carcinoma. Presented at Liver Disease awareness week 2014 ... External Beam Radiotherapy for Hepatocellular carcinoma * 1. Latest advances in radiotherapy for hepatocellular carcinoma Liver ... Latest advances in external beam radiotherapy for hepatocellulalar carcinoma. Presented at Liver Disease awareness week 2014 ...
more infohttps://www.slideshare.net/balavellay/external-beam-radiotherapy-for-hepatocellular-carcinoma

Hepatocellular Carcinoma BlogsHepatocellular Carcinoma Blogs

Hepatocellular carcinoma (HCC) with a focus on diagnosis and screening. (Source: Notes from Dr. RW). Source: Notes from Dr. RW ... Rapid Hepatocellular Carcinoma Test Can be Administered Anywhere. Researchers at the University of Utah have developed a rapid ... Hepatocellular Carcinoma Blogs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to ... Hepatocellular Carcinoma : Triple Phase CT. Presenting brief teaching video under the DAMS Unplugged series on HCC and imaging ...
more infohttps://medworm.com/hepatocellular-carcinoma/blogs/

Hepatocellular CarcinomaHepatocellular Carcinoma

Home , Books , Hepatocellular Carcinoma View PDF. Hepatocellular Carcinoma. Publication Year: 2008. Edition: 1st. Authors/ ... Hepatocellular Carcinoma is included in the following Collections:. *Ovid Gastroenterology & Hepatology Book Package ... Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics - including those more controversial ... This volume is therefore an important contribution to the field of hepatocellular carcinoma. ...
more infohttp://www.ovid.com/site/catalog/books/8668.jsp

Hepatocellular Carcinoma (HCC) Symptoms & TreatmentHepatocellular Carcinoma (HCC) Symptoms & Treatment

Learn more about hepatocellular carcinoma, including its symptoms, risks, and treatment options. ... Diagnosing Hepatocellular Carcinoma. Symptoms of hepatocellular carcinoma. Many people with hepatocellular carcinoma (HCC) have ... Hepatocellular Carcinoma Overview. Hepatocellular carcinomas (HCC) are also known as primary liver cancers, hepatic tumors, or ... Testing for hepatocellular carcinoma. In addition to a physical exam, your doctor may order the following tests to help ...
more infohttps://www.upmc.com/services/liver-cancer/conditions/hepatocellular-carcinoma

Liver cancer - hepatocellular carcinoma: MedlinePlus Medical EncyclopediaLiver cancer - hepatocellular carcinoma: MedlinePlus Medical Encyclopedia

Hepatocellular carcinoma is cancer that starts in the liver. ... Hepatocellular carcinoma is not the same as metastatic liver ... Hepatocellular carcinoma accounts for most liver cancers. This type of cancer occurs more often in men than women. It is ... To accurately diagnose hepatocellular carcinoma, a biopsy of the tumor must be done. ...
more infohttps://medlineplus.gov/ency/article/000280.htm

hepatocellular carcinoma | Guthepatocellular carcinoma | Gut

Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma Jessica Liu, Hwai-I Yang, ... Hepatitis B virus seromarkers clearance and risk of hepatocellular carcinoma: serious risks of misinterpretation Alexandre ... Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment Gianluigi ... Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension ...
more infohttps://gut.bmj.com/keyword/hepatocellular-carcinoma?page=8

Hepatocellular carcinoma: Resection vs. transplantation | EurekAlert! Science NewsHepatocellular carcinoma: Resection vs. transplantation | EurekAlert! Science News

Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this ... Hepatocellular carcinoma: Resection vs. transplantation. Deutsches Aerzteblatt International. Journal. Deutsches Ärzteblatt ... From the published studies, they analyzed a subgroup consisting of patients with earlier hepatocellular carcinoma (HCC) in ... Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this ...
more infohttps://www.eurekalert.org/pub_releases/2017-09/dai-hcr090817.php

Hepatocellular carcinoma Disease Reference Guide - Drugs.comHepatocellular carcinoma Disease Reference Guide - Drugs.com

Hepatocellular carcinoma (HCC) - Learn about innovative treatment of HCC liver cancer, including liver transplant, ablation and ... Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in ... Hepatocellular carcinoma treatments include:. *Surgery. Surgery to remove the cancer and a margin of healthy tissue that ... Which treatment is best for you will depend on the size and location of your hepatocellular carcinoma, how well your liver is ...
more infohttps://www.drugs.com/mcd/hepatocellular-carcinoma

Liver Cell Adenoma or Hepatocellular Carcinoma?Liver Cell Adenoma or Hepatocellular Carcinoma?

Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the ...
more infohttp://www.medindia.net/news/Liver-Cell-Adenoma-or-Hepatocellular-Carcinoma-48986-1.htm

Surveillance for Hepatocellular Carcinoma in Patients With CirrhosisSurveillance for Hepatocellular Carcinoma in Patients With Cirrhosis

Are patients with cirrhosis particularly vulnerable to developing hepatocellular carcinoma, and how should they be screened for ... Journal Article Risk of Hepatocellular Carcinoma in Non-alcoholic Steatohepatitis Without Cirrhosis Compared to Other Liver ... thus meeting the radiographic diagnosis criteria for hepatocellular carcinoma (HCC) of the American Association for the Study ... of Chronic Hepatitis C With Direct-acting Antivirals Does Not Change the Short-term Risk for De Novo Hepatocellular Carcinoma ...
more infohttps://www.medscape.com/viewarticle/756445

Hepatocellular Carcinoma Arising in Non-Cirrhotic HaemochromatosisHepatocellular Carcinoma Arising in Non-Cirrhotic Haemochromatosis

... N. P. Thompson, G. Stansby, M. Jarmulowicz, K. E. Hobbs, ... Hepatocellular carcinoma arising in a patient with genetic haemachromatosis, without cirrhosis, has only been described once ... We present a patient with a 15 year history of genetic haemachromatosis who underwent resection of a hepatocellular carcinoma ...
more infohttps://www.hindawi.com/journals/hpb/1995/046986/abs/

Management of Hepatocellular Carcinoma: Updated ReviewManagement of Hepatocellular Carcinoma: Updated Review

Hepatocellular carcinoma (HCC) represents one of the most challenging potentially curable tumors with high incidence, ... "Management of Hepatocellular Carcinoma: Updated Review" written by Tamer Elbaz, Mohamed El Kassas, Gamal Esmat, published by ... score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma ... score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma ...
more infohttps://www.scirp.org/Journal/papercitationdetails.aspx?PaperID=29746&JournalID=125

Hepatocellular Carcinoma News Page 9Hepatocellular Carcinoma News Page 9

Risk Factors for Hepatocellular Carcinoma in the USRisk Factors for Hepatocellular Carcinoma in the US. Who is most at risk for ... Risk Factors for Hepatocellular Carcinoma in HCV PatientsRisk Factors for Hepatocellular Carcinoma in HCV Patients. Under what ... Treating Hepatocellular Carcinoma After First-line SorafenibTreating Hepatocellular Carcinoma After First-line Sorafenib. How ... Scirrhous hepatocellular carcinoma, a rare subtype of hepatocellular carcinoma, can be difficult to distinguish from other ...
more infohttps://medworm.com/hepatocellular-carcinoma/news/9/
  • Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics - including those more controversial ones - in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross pathology, from screening to atypical presentation, from diagnosis to treatment, and from assessment to choice of appropriate treatment. (ovid.com)
  • In a gastronomic tour of some of the many food descriptors used in medicine, the author highlights imagery such as 'anchovy sauce' to describe the pus from a liver abscess, through 'sago spleen' to indicate protein (amyloid) deposits, to 'oat cell carcinoma,' which describes the appearance of a highly aggressive form of lung cancer. (medworm.com)
  • Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake," Journal of Hepatology , vol. 54, no. 4, pp. 705-715, 2011. (hindawi.com)
  • A suspected contributor to this increased risk is circulating insulin concentration such that diabetics with poor insulin control or on treatments that elevate their insulin output (both states that contribute to a higher circulating insulin concentration) show far greater risk of hepatocellular carcinoma than diabetics on treatments that reduce circulating insulin concentration. (wikipedia.org)
  • Advances in molecular characterization and novel gene-isolation techniques have vigorously expanded our understanding of hepatocellular carcinoma (HCC), a form of liver cancer that affects one million people annually, and generated many new therapeutic possibilities. (springer.com)